RxDoctor Payments DataLook up a doctor →

Amit Malhotra, MD

Interventional Cardiology · Southaven, MSNPI 1699724294

Payments from drug & device makers

$131,148in general payments, 2019–2025

Across 469 payments — averaging $279.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Somavac Medical Solutions, Inc.$90K
  • Cardiovascular Systems Inc.$27K
  • Bard Peripheral Vascular, Inc.$3K
  • Abbott$1K
  • Philips North America LLC$1K
  • AstraZeneca$998
  • plus $7K from 33 others

What the payments were for

  • Food & beverage$10,281100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$131,148 in reported general payments places this provider in the 85th percentile of 65 interventional cardiology providers in Mississippi.

See all interventional cardiology providers in Mississippi

Medicare billing

Part B allowed, 2024
$432,165
Medicare patients
1,836
Services billed
7,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban845$807,273
EntrestoSacubitril/Valsartan643$581,391
FarxigaDapagliflozin Propanediol357$338,007
JardianceEmpagliflozin332$322,165
XareltoRivaroxaban299$254,285
Repatha SureclickEvolocumab270$220,330
MultaqDronedarone Hcl31$41,146
OzempicSemaglutide29$37,927
VascepaIcosapent Ethyl48$25,544
Praluent PenAlirocumab21$18,142
Nebivolol Hcl346$16,488
BrilintaTicagrelor15$15,821
MounjaroTirzepatide11$15,742
Amiodarone Hcl526$13,613
Ranolazine ErRanolazine144$12,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$473$807,273845 claims
NovartisEntresto$867$581,391643 claims
AstraZenecaFarxiga, Brilinta$998$353,828372 claims
Boehringer IngelheimJardiance$169$322,165332 claims
Johnson & JohnsonXarelto$130$254,285299 claims
Sanofi-aventis U.S. LLCMultaq$143$41,14631 claims
Novo NordiskOzempic$191$37,92729 claims
MerckVerquvo$367$11,28813 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$30$8,20719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 65 interventional cardiology providers in Mississippi.

Other interventional cardiology in Southaven

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →